文献速递头颈部肿瘤放疗

头颈部鳞状细胞癌患者术后(放)化疗——临床合作小组「头颈部癌症个体化放疗」队列的临床结果

Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
PubMed 文献 · Radiat Oncol · 2018-07-03

该研究回顾性(至2013年)及前瞻性(自2013年)收集2008年6月至2015年6月在慕尼黑大学医院放疗科接受术后(放)化疗的口腔、口咽、下咽或喉部头颈部鳞状细胞癌患者数据,分析结局与治疗失败。共纳入302例患者(中位随访45个月,平均年龄60.7岁),中位放疗剂量64 Gy,58%联合化疗。3年总生存率、局部、局部区域和远处失败估计分别为70.5%、9.7%、12.2%和13.5%。

要点

  • 302例头颈部鳞癌患者接受术后(放)化疗,中位随访45个月,中位剂量64 Gy,58%联合化疗。
  • 3年总生存率70.5%,局部失败9.7%,局部区域失败12.2%,远处失败13.5%。
  • 多因素分析中,HPV相关口咽癌与总生存及肿瘤控制改善显著相关。

核心结论

  • 该队列为大型未经选择的接受术后(放)化疗的头颈部鳞状细胞癌患者队列,肿瘤控制率与生存率与既往报道数据一致。

研究设计与样本

  • 回顾性(至2013年)及前瞻性(自2013年)收集2008年6月至2015年6月在慕尼黑大学医院放疗科接受术后(放)化疗的口腔、口咽、下咽或喉部头颈部鳞状细胞癌患者数据,分析结局与治疗失败。
  • 共纳入302例患者,中位随访45个月,平均年龄60.7岁,中位放疗剂量64 Gy,58%的病例联合化疗,化疗多为顺铂/5-氟尿嘧啶,与ARO 96-3研究一致。

主要发现

  • 3年总生存率、局部失败、局部区域失败和远处失败估计分别为70.5%、9.7%、12.2%和13.5%。
  • 多因素分析中,人乳头瘤病毒相关口咽癌与显著改善的总生存率、局部区域控制率、远处控制率和总体肿瘤控制率相关。
  • 多因素分析中,局部失败方面,切缘状态和神经周围侵犯为显著不良因素;局部区域失败和远处失败方面,包膜外侵犯为显著不良因素;总生存方面,淋巴结病变存在为显著不良因素。
  • 138例患者按照ARO 96-3方案治疗,结果与本研究一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative (chemo) radiation improves tumor control and survival in high-risk patients with head and neck squamous cell carcinoma based on established risk factors. The clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer" focuses on the identification and validation of new biomarkers, which are aimed at eventually stratifying and personalizing the therapy concept. Hence, we reviewed all patients with head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, treated with postoperative (chemo) radiation from 06/2008 until 06/2015 at the Department of Radiation Oncology in the University Hospital, LMU Munich. Here we report the clinical results of the cohort, laying the foundation for further research within the framework of a clinical cooperation group. METHODS: Patient data were retrospectively (until 2013) and prospectively (from 2013) collected and analyzed for outcome and treatment failures with regard to previously described and established risk factors. RESULTS: We identified 302 patients (median follow-up 45 months, average age 60.7 years), having received postoperative (chemo)radiation (median 64 Gy). Chemotherapy was added in 58% of cases, mostly Cisplatin/5- Fluorouracil in concordance with the ARO 96-3 study. The 3-year overall survival, local, locoregional and distant failure estimates were 70.5, 9.7, 12.2 and 13.5%, respectively. Human papillomavirus-associated oropharyngeal cancer was associated with a significant improved overall survival, locoregional, distant and overall tumor control rates in multivariate analysis. Additionally, in multivariate analysis, for local failure, resection status and perineural invasion, for locoregional and distant failure extracapsular extension and for overall survival the presence of nodal disease were significant adverse factors. Moreover, 138 patients have been treated in concordance with the ARO 96-3 protocol, corroborating the results of this study. CONCLUSIONS: Our cohort represents a large unselected cohort of patients with head and neck squamous cell carcinoma treated with postoperative (chemo)radiation. Tumor control rates and survival rates are consistent with the results of previously reported data.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Maihoefer C, Schüttrumpf L, Macht C, et al. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". Radiat Oncol. 2018. PMID: 29970111. doi:10.1186/s13014-018-1067-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。